NORTHLAND

NORTHLAND

Language

NORTHLAND has been approved to establish a postdoctoral research workstation, cultivating high-end professional talents.

发布时间：2024-12-12

On December 12, 2024, the annual Postdoctoral Talent Development Conference, hosted by the Beijing Municipal Bureau of Human Resources and Social Security, was held at the Beijing International Wealth Center. At the conference, our company was awarded the plaque for a Postdoctoral Research Workstation jointly issued by the Ministry of Human Resources and Social Security and the National Postdoctoral Administration Committee. This recognition marks another step forward for our company following the award in 2023 of the title “Beijing Postdoctoral Innovation and Practice Base,” highlighting our firm commitment to advancing technological innovation and cultivating high-end professional talent, as well as our vigorous and upward trajectory of development.

09

2024-10

NORTHLAND Shanghai Branch Officially Opens, Fully Deploying the Commercialization of NL003

发布时间：2024-10-09

On October 9, 2024, NORTHLAND's Shanghai branch officially opened with great fanfare at the Lifeng Skyline Center in Jing'an District. Chairman Xu Songsan led the management team and members of the sales team to attend the opening ceremony. Han Yi, Deputy Secretary of the Party Working Committee of the Suhe Bay Management Committee of Shanghai Municipality; Gu Wei, Deputy Secretary of the Party Working Committee of the Tianmu West Road Subdistrict Office in Jing'an District; and Lan Tian, Deputy Director of the same office, along with leaders from Zhongtai Securities, Fuguo Fund, Guotai Junan, and Ocumetics, attended the ceremony to jointly witness and celebrate the opening of NORTHLAND's Shanghai branch.

27

2024-09

Good News: NORTHLAND NL003 Has Passed the Drug Registration Inspection.

发布时间：2024-09-27

On September 26, 2024, our company’s independently developed Class 1 therapeutic biological product—Donaperminogene Seltoplasmid Injection, “Recombinant Human Hepatocyte Growth Factor Naked Plasmid Injection” (code name NL003)—obtained the “Drug Registration Inspection Report” and the “Review Opinion on Drug Registration Inspection Standards” issued by the China National Institute for Food and Drug Control. The report stated: “This product, when tested according to the declared quality standards, has met all specified requirements.” This marks that both the NL003 bulk substance and its finished formulation have successfully passed the pre-registration inspection, confirming that the product meets the required quality standards and bringing the new drug registration review one step closer to completion.

03

2024-09

NORTHLAND Successfully Held the 2024 Half-Year Results Briefing, Demonstrating Strong Growth Momentum

发布时间：2024-09-03

Beijing Northland Biotechnology Co., Ltd. (stock code: 430047, stock abbreviation: NORTHLAND) successfully held its 2024 Semiannual Results Briefing on the afternoon of September 2, 2024. The purpose of this meeting was to provide investors with a comprehensive overview of the company's operating performance, financial condition, and future development plans for the first half of 2024, thereby further enhancing investors' understanding and confidence in the company. The meeting attracted participation and attention from representatives of more than 50 institutions and individual investors, achieving positive results in communication and exchange.

16

2024-08

The Phase III clinical trial (rest pain protocol) of China’s first naked plasmid gene therapy drug for the treatment of lower limb ischemic disease has been unblinded. The results are consistent with expectations.

发布时间：2024-08-16

On August 16, 2024, the Phase III clinical trial of NORTHLAND’s “Recombinant Human Hepatocyte Growth Factor Naked Plasmid Injection” (code-named NL003) for the treatment of lower limb ischemic disease—specifically targeting rest pain—was unblinded according to the pre-established schedule, and the primary endpoints met expectations. Preliminary results indicate that, in terms of the primary endpoint—the rate of complete pain relief at 180 days—the NL003 group significantly outperformed the placebo control group (p<0.0001). The product demonstrated a favorable safety profile, with no serious adverse reactions related to the drug identified.

15

2024-08

A systematic review and meta-analysis paper on the use of recombinant human hepatocyte growth factor naked plasmid for the treatment of chronic ischemic diseases has been published in a prestigious European journal.

发布时间：2024-08-15

Recently, a systematic review and meta-analysis on the use of naked plasmid encoding recombinant human hepatocyte growth factor for the treatment of chronic ischemic diseases was published in the European Journal of Vascular & Endovascular Surgery (impact factor: 5.7). The co-first authors of this paper are Dr. Xiao Di and Dr. Peng Wang from the Department of Vascular Surgery at Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, while the corresponding author is Professor Changwei Liu.

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Friendly Links: Baidu | NORTHLAND

NORTHLAND

Contact Information

Address: Room A406, Zhongguancun Biomedical Park, No. 5 Kaituo Road, Shangdi, Haidian District, Beijing

Hotline: +86 010-82890893

Email: northland@northland-bio.com

Website: www.northland-bio.com

Complaints Reporting Hotline: +86 010-82890893-8031

Complaints Reporting Email: pv@northland-bio.com

Follow Us

Northland is an innovative biopharmaceutical company specializing in the R&D, manufacturing and sales of gene therapy drugs, recombinant protein drugs and ophthalmic medications.

WeChat Mini Program

Web site

WeChat Official Account

NL-BIO

Scientific Research on Lower Limb Ischemia

NL003

Myocardial Infarction Scientific Research

NL005

Business license

Powered by 300.cn  Privacy Policy